Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 13/20 | 0.50 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GGT1 | P19440 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salsalate SCHEMBL668243 | 0.84 | KDM4E (0.52) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| Phthalic Acid SCHEMBL5048545 | 0.83 | ALDH1A1 (0.47) | KDM4EHPGDALDH1A1TSHRBLM | |
| Aspirin SCHEMBL10787619 | 0.83 | PTGS2 (0.50) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL191054 | 0.82 | KDM4E (0.67) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL162391 | 0.82 | KDM4E (0.67) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL1457620 | 0.82 | KDM4E (0.67) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL26228 | 0.82 | KDM4E (0.67) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL7250097 | 0.82 | KDM4E (0.67) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL21328428 | 0.82 | KDM4E (0.67) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL24830 | 0.82 | KDM4E (0.67) | PTGS2KDM4EHSD17B10HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058452-A1 | PHARMACEUTICAL COMPOSITION CONTAINING TEMPERATURE-RESPONSIVE IONIC LIQUID | TORAY INDUSTRIES, INC. (JP) | 2024-02-22 | — | — | US | disclosed |
| EP-4043007-A1 | PHARMACEUTICAL COMPOSITION INCLUDING TEMPERATURE-RESPONSIVE IONIC LIQUID | Toray Industries, Inc. (JP) | 2022-08-17 | — | — | EP | disclosed |
| CN-114502142-A | Pharmaceutical compositions comprising temperature-responsive ionic liquids | 东丽株式会社 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021070893-A1 | PHARMACEUTICAL COMPOSITION INCLUDING TEMPERATURE-RESPONSIVE IONIC LIQUID | 東レ株式会社 | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240058452-A1 | PHARMACEUTICAL COMPOSITION CONTAINING TEMPERATURE-RESPONSIVE IONIC LIQUID | SULT1A1, CYP2C19, SULT2A1 | PTGS2 2070/4885PTGS1 1909/4885KDM4E 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.